在实际临床实践中对罗氟司特不耐受。 - Suppr

Suppr

超能文献

Intolerance to roflumilast in real-life clinical practice.

作者信息

Gómez-Rodríguez Mónica, Golpe Rafael

机构信息

Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain.

出版信息

Eur J Intern Med. 2017 Sep;43:e28-e29. doi: 10.1016/j.ejim.2017.04.019. Epub 2017 May 2.

DOI:10.1016/j.ejim.2017.04.019

PMID:28476325

Abstract

摘要

相似文献

Intolerance to roflumilast in real-life clinical practice.在实际临床实践中对罗氟司特不耐受。

Eur J Intern Med. 2017 Sep;43:e28-e29. doi: 10.1016/j.ejim.2017.04.019. Epub 2017 May 2.

Roflumilast for chronic obstructive pulmonary disease.罗氟司特用于慢性阻塞性肺疾病

Lancet. 2005 Nov 26;366(9500):1845-6; author reply 1846-7. doi: 10.1016/S0140-6736(05)67748-3.

[Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].[罗氟司特：慢性阻塞性肺疾病炎症治疗新选择的临床综述]

Arch Bronconeumol. 2010 Nov;46 Suppl 9:8-11. doi: 10.1016/S0300-2896(10)70047-8.

Roflumilast (Daliresp) for COPD.罗氟司特（达力释）用于慢性阻塞性肺疾病。

Med Lett Drugs Ther. 2011 Jul 25;53(1369):59-60.

What is the role of roflumilast in chronic obstructive pulmonary disease?罗氟司特在慢性阻塞性肺疾病中起什么作用？

Cleve Clin J Med. 2017 Jan;84(1):13-15. doi: 10.3949/ccjm.84a.15150.

[Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].罗氟司特：慢性阻塞性肺疾病治疗的新方法

Med Monatsschr Pharm. 2010 Jul;33(7):236-43.

The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease.监管机构对罗氟司特的不同意见令人费解，但我们需要治疗慢性阻塞性肺疾病的新药。

Ther Adv Respir Dis. 2010 Aug;4(4):195-8. doi: 10.1177/1753465810377636.

Roflumilast: A Review in COPD.罗氟司特：在 COPD 中的应用评价。

Drugs. 2015 Sep;75(14):1645-56. doi: 10.1007/s40265-015-0463-1.

Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.减轻疾病负担并改善肺功能——罗氟司特：获批用于中重度慢性阻塞性肺疾病：临床护理专家的最新资讯

Clin Nurse Spec. 2011 Jul-Aug;25(4):176-7. doi: 10.1097/NUR.0b013e31822229a9.

Roflumilast for severe COPD?罗氟司特用于重度慢性阻塞性肺疾病？

Drug Ther Bull. 2011 Apr;49(4):45-8; quiz iii-iv. doi: 10.1136/dtb.2011.02.0025.

引用本文的文献

Phosphodiesterase Inhibition as a Therapeutic Strategy for Chronic Obstructive Pulmonary Disease: Where We Have Been and What Lies Ahead.磷酸二酯酶抑制作为慢性阻塞性肺疾病的一种治疗策略：我们的历程与未来方向

Chronic Obstr Pulm Dis. 2025 Jan 29;12(1):82-92. doi: 10.15326/jcopdf.2024.0559.

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study.在 COPD 中新型吸入型 PDE4 抑制剂 CHF6001 的疗效和安全性：PIONEER 研究。

Respir Res. 2020 Sep 22;21(1):246. doi: 10.1186/s12931-020-01512-y.

Efficacy and safety profile of roflumilast in a real-world experience.罗氟司特在真实世界中的疗效和安全性概况。

J Thorac Dis. 2019 Apr;11(4):1100-1105. doi: 10.21037/jtd.2019.04.49.

Effects of Roflumilast on Rehospitalization and Mortality in Patients.罗氟司特对患者再住院率和死亡率的影响。

Chronic Obstr Pulm Dis. 2018 Dec 20;6(1):74-85. doi: 10.15326/jcopdf.6.1.2018.0139.

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.用于治疗炎症性疾病的磷酸二酯酶-4抑制剂

Front Pharmacol. 2018 Oct 17;9:1048. doi: 10.3389/fphar.2018.01048. eCollection 2018.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验